Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high
- Author(s)
- Grigg, S; Minson, A; Prins, E; Dickinson, MJ;
- Details
- Publication Year 2024-07,Volume 205,Issue #1,Page 122-126
- Journal Title
- British Journal of Haematology
- Publication Type
- Research article
- Abstract
- We reviewed cases with aggressive B-cell non-Hodgkin lymphoma who relapsed or progressed following glofitamab. The prognosis was poor, with low rates of response to subsequent salvage therapies, and a median overall survival of 4.1 months from the time of progression. There were high rates of CD20 loss (59%) at the time of relapse. In a field where CD20 × CD3 bispecific antibodies are entering routine clinical use, our experience highlights a potential means of resistance. It illustrates both the need to further characterise mechanisms of CD20 loss, and to pursue clinical trials of novel non-CD20-directed treatments in this cohort.
- Publisher
- Wiley
- Keywords
- Humans; *Antigens, CD20; Male; Female; Middle Aged; Aged; Prognosis; *Antibodies, Bispecific/therapeutic use; Recurrence; Adult; Aged, 80 and over; Lymphoma, B-Cell/mortality/drug therapy; immunotherapy; lymphoid malignancies; lymphomas
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1111/bjh.19455
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-01 05:00:17
Last Modified: 2024-08-01 05:00:43